The Alzheimer's field has had its share of clinical trial flops.
Now there's a push to learn from past failures. Computational scientists
in pharmaceutical companies are guiding clinical trial design by first
putting drug candidates through their paces in simulations. Those are
proprietary, but C-Path’s Coalition Against Major Diseases has built
some open-access simulation tools…
No comments:
Post a Comment